These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 20800401)
1. PET/CT with 68Gallium-DOTA-peptides in NET: an overview. Ambrosini V; Campana D; Tomassetti P; Grassetto G; Rubello D; Fanti S Eur J Radiol; 2011 Nov; 80(2):e116-9. PubMed ID: 20800401 [TBL] [Abstract][Full Text] [Related]
2. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Naswa N; Sharma P; Kumar A; Nazar AH; Kumar R; Chumber S; Bal C AJR Am J Roentgenol; 2011 Nov; 197(5):1221-8. PubMed ID: 22021518 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077 [TBL] [Abstract][Full Text] [Related]
4. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441 [TBL] [Abstract][Full Text] [Related]
5. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Ambrosini V; Campana D; Tomassetti P; Fanti S Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S52-60. PubMed ID: 22388622 [TBL] [Abstract][Full Text] [Related]
7. When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors? Fuccio C; Musto A; Cambioli S; Castellucci P; Pantaleo MA; Nanni C; Montini GC; Campana D; Tomassetti P; Bellan E; Massaro A; Grassetto G; Rubello D; Fanti S Clin Nucl Med; 2011 Dec; 36(12):1109-11. PubMed ID: 22064082 [No Abstract] [Full Text] [Related]
8. 68Ga-DOTA-peptides in the diagnosis of NET. Ambrosini V; Fanti S PET Clin; 2014 Jan; 9(1):37-42. PubMed ID: 25029932 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Fanti S; Ambrosini V; Tomassetti P; Castellucci P; Montini G; Allegri V; Grassetto G; Rubello D; Nanni C; Franchi R Biomed Pharmacother; 2008 Dec; 62(10):667-71. PubMed ID: 18358680 [TBL] [Abstract][Full Text] [Related]
10. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. Kulkarni HR; Baum RP PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937 [TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides? Sharma P; Mukherjee A; Bal C; Malhotra A; Kumar R AJR Am J Roentgenol; 2013 Dec; 201(6):1340-7. PubMed ID: 24896203 [TBL] [Abstract][Full Text] [Related]
13. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518 [TBL] [Abstract][Full Text] [Related]
14. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary? Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539 [TBL] [Abstract][Full Text] [Related]
16. 68Ga DOTANOC PET/CT in primary neuroendocrine tumor of the breast. Mukherjee A; Karunanithi S; Singla S; Bal C; Kumar R Clin Nucl Med; 2014 Apr; 39(4):396-8. PubMed ID: 24566407 [TBL] [Abstract][Full Text] [Related]
17. What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use? Ballinger JR; Solanki KK Nucl Med Commun; 2011 Dec; 32(12):1109-12. PubMed ID: 21934542 [No Abstract] [Full Text] [Related]